Ibrutinib for Chronic Lymphocytic Leukemia

被引：0
|
作者：
Sharman, Jeff P. [1 ]
Mato, Anthony R. [2 ]
Keating, Michael J. [3 ]
机构：
[1] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 16期
关键词：
PREVIOUSLY UNTREATED PATIENTS; CHLORAMBUCIL; THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1592 / 1593
页数：2
相关论文
共 50 条
  • [31] Acanthamoeba Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
    Persico, Michele
    Saklawi, Youssef
    Balaji, Dhiksha
    Park, Sam
    Collins, Jeffrey
    ANNALS OF NEUROLOGY, 2024, 96 : S262 - S263
  • [32] Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
    Bachireddy, Pavan
    Wu, Catherine J.
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1547 - 1549
  • [33] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 16 - 17
  • [34] Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
    Komarova, Natalia L.
    Burger, Jan A.
    Wodarz, Dominik
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (38) : 13906 - 13911
  • [35] The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia
    Molica, Stefano
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 543 - 546
  • [36] Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
    Hing, Zachary A.
    Mantel, Rose
    Beckwith, Kyle A.
    Guinn, Daphne
    Williams, Erich
    Smith, Lisa L.
    Williams, Katie
    Johnson, Amy J.
    Lehman, Amy M.
    Byrd, John C.
    Woyach, Jennifer A.
    Lapalombella, Rosa
    BLOOD, 2015, 125 (20) : 3128 - 3132
  • [37] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 13 - 14
  • [38] Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
    Burger, Jan A.
    Sivina, Mariela
    Jain, Nitin
    Kim, Ekaterina
    Kadia, Tapan
    Estrov, Zeev
    Nogueras-Gonzalez, Graciela M.
    Huang, Xuelin
    Jorgensen, Jeffrey
    Li, Jianling
    Cheng, Mei
    Clow, Fong
    Ohanian, Maro
    Andreeff, Michael
    Mathew, Thomas
    Thompson, Philip
    Kantarjian, Hagop
    O'Brien, Susan
    Wierda, William G.
    Ferrajoli, Alessandra
    Keating, Michael J.
    BLOOD, 2019, 133 (10) : 1011 - 1019
  • [39] Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
    Jain, Preetesh
    Keating, Michael
    Wierda, William
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    George, Binsah
    James, Danelle
    Kantarjian, Hagop
    Burger, Jan
    O'Brien, Susan
    BLOOD, 2015, 125 (13) : 2062 - 2067
  • [40] Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells
    Xia, Meihui
    Luo, Tina Yuxuan
    Shi, Yonghong
    Wang, Guizhi
    Tsui, Hubert
    Harari, Daniel
    Spaner, David E.
    JOURNAL OF IMMUNOLOGY, 2020, 205 (10): : 2629 - 2639
12345